Amylyx (AMLX) | Stock Overview & Key Data

Amylyx Pharmaceuticals Inc. | Small-cap | Healthcare

$6.41

27.69%

| Amylyx Stock Comparison:

Amylyx vs Vertex Amylyx vs Regeneron Amylyx vs Vera Therapeutics Amylyx vs Immunocore Holdings Amylyx vs Agios Amylyx vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Amylyx Performance Comparison

Loading chart data...

Amylyx

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $5.31 High: $6.70

on June 24, 2025

52 Week Range

Low: $1.62 High: $7.27

on July 9, 2024

on November 8, 2024

All-Time High: $41.93 on January 30, 2023

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $447.5M

EPS i -3.10

P/E Ratio (TTM) i 2.54

Forward P/E i -2.71

P/B Ratio i 2.22

PEG Ratio i -2.71

Div. Yield i N/A

ROE i -83.24%

Beta i -0.587

Debt to Equity i 0.69

Financial Highlights

Profitability

Gross Margin i N/A

Operating Margin i 16,317.06%

Profit Margin i -42.65%

Returns and Earnings

Return on Assets (TTM) i -40.72%

Return on Equity (TTM) i -83.24%

EBITDA i $-206.8M

Net Income (TTM) i $-218.9M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i N/A

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Amylyx AMLX	447.49M Small-cap	20.26%	35.81%	69.58%	60.25%	63.94%	164.21%	-74.22%	-72.22%
Vertex VRTX	116.96B Large-cap	1.87%	0.96%	-12.01%	10.31%	10.97%	-5.37%	54.37%	52.37%
Regeneron REGN	55.27B Large-cap	2.64%	-13.43%	-20.99%	-26.90%	-26.97%	-51.29%	-14.02%	-17.76%
Vera Therapeutics VERA	1.45B Small-cap	6.76%	18.59%	-16.83%	-46.14%	-46.49%	-40.16%	63.15%	88.26%
Immunocore Holdings IMCR	1.56B Small-cap	-1.08%	-0.09%	8.00%	11.69%	7.34%	-8.17%	-16.66%	-27.96%
Agios AGIO	1.93B Small-cap	-3.66%	10.66%	3.44%	-2.25%	4.96%	-22.68%	42.72%	-40.13%

Ownership & Short Interest

Insider Ownership i 12.47%

Institutional Ownership i 85.88%

Shares Short i 4M

Short Ratio i 3.77

Short % of Shares Outstanding i 5.11%

Average 10-Day Volume i 984K

Average 90-Day Volume i 935K

Amylyx Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Amylyx would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is AMLX's 52-week high and low?

In the last 52 weeks, Amylyx reached a high of $7.27 (on November 8, 2024) and a low of $1.62 (on July 9, 2024).

What is the market cap and P/E ratio for AMLX?

Curious about Amylyx's size and valuation? Its market capitalization stands at 447.49M. When it comes to valuation, the P/E ratio (trailing twelve months) is 2.54, and the forward P/E (looking ahead) is -2.71.

Does AMLX pay dividends? If so, what's the yield?

As for dividends, Amylyx isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Amylyx's main competitors or similar companies to consider before investing?

When looking at Amylyx, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	116.96B	Healthcare	Biotechnology	-5.37%	54.37%
Regeneron REGN	55.27B	Healthcare	Biotechnology	-51.29%	-14.02%
Vera Therapeutics VERA	1.45B	Healthcare	Biotechnology	-40.16%	63.15%
Immunocore Holdings IMCR	1.56B	Healthcare	Biotechnology	-8.17%	-16.66%
Agios AGIO	1.93B	Healthcare	Biotechnology	-22.68%	42.72%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Amylyx Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Amylyx's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -83.24%, the Debt to Equity ratio from the most recent quarter is 0.69, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for AMLX?

Looking at Amylyx's growth, its revenue over the trailing twelve months (TTM) was $-1M. Compared to the same quarter last year (YoY), quarterly revenue grew by -100.00%, and quarterly earnings saw a YoY growth of N/A.

How much of AMLX stock is held by insiders and institutions?

Wondering who owns Amylyx stock? Company insiders (like executives and directors) hold about 12.47% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 85.88%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.